XXXX mustard, @entity1891 , @entity4174 , and @entity617 for relapse after radiation in @entity978 . An analysis of long-term follow-up.

@entity1 @entity1568 @entity4174 @entity353 @entity3052 @entity1891 @entity978 @entity617
One hundred and sixty-one @entity1 who were treated with @entity1568 mustard, @entity1891 , @entity4174 , and @entity617 (MOPP) chemotherapy for @entity978 have been observed for a median of 10.2 years. Eighty-two percent of those @entity1 received MOPP after relapse from previous irradiation. The complete response (CR) rate was 71%. For the 116 @entity1 achieving CR the relapse-free survival at 5 years was 83% and at 10 years, 79%. The overall survival was 72% at 5 years and 64% at 10 years. In a stepwise logistic regression analysis the most important clinical factors influencing response were B symptoms at presentation (fever greater than 38 degrees C, night sweats, @entity353 greater than 10% of body weight), histologic subtype, and lung or pleural involvement. @entity1 who received MOPP as first-line therapy had a significantly worse response rate than those who received MOPP upon relapse after radiotherapy. This difference is reduced when adjustments are made for the presence of the above prognostic factors. A Cox regression analysis showed that Stage IV at presentation and lymphocyte-depleted histology were the most important factors indicating reduced survival. @entity1 who achieved a CR to MOPP had a significantly improved survival. Of the 65 @entity1 who had died at the time of the analysis of this series, 46 died of progressive @entity978 . All four @entity1 who developed secondary @entity3052 had received radiation as well as MOPP.
